NCT06004661 2026-03-06
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
Novartis
Phase 2 Recruiting
Novartis
Oncopeptides AB
Celgene
Novartis
Amgen
Pierre Fabre Medicament